Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene (This gene does not contain this module)
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: RPS4Y1

Summary for RPS4Y1

Gene information	Gene symbol	RPS4Y1
	Ensembl ID	ENSG00000129824
	Entrez ID	6192
	Gene name	ribosomal protein S4 Y-linked 1
	Synonyms	MGC119100\|MGC5070\|RPS4Y\|S4
	Gene type	protein_coding
	UniProtAcc	P22090

Top

Dataset with differentially expressed gene: RPS4Y1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.986063	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.555155	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	NK cells	-0.595915	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	-1.09011	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Progenitors	-1.7218	1.39e-22
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD4+ T cells	-1.48235	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	Mono/Macro	-0.729131	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	cDCs	-0.816716	9.00e-42
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	CD8+ T cells	-0.837917	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	NK cells	-0.331511	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	0.37361	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.516375	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.272416	1.05e-02
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	-0.422511	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.467758	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-1.12727	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	-0.750502	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	-0.354445	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-1.78457	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-0.440666	4.89e-05
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.302518	2.06e-16
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	-0.315037	4.57e-38
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	-0.251496	3.22e-07
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.633722	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.665702	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	-0.330634	1.47e-27
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	cDCs	1.00808	1.27e-05
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	B cells	0.956244	9.08e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD4+ T cells	0.975752	4.95e-09
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.781699	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.843635	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.598689	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.624075	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	1.13142	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	cDCs	0.854802	1.45e-06
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.627234	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	0.596936	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	0.398036	5.99e-10
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	NK cells	0.637313	2.69e-18
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	pDCs	0.829403	4.23e-03
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.493803	3.15e-36
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	1.05243	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	0.484122	2.58e-02
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD8+ T cells	0.57097	8.15e-25
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	NK cells	0.422802	9.12e-08
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	0.37045	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD4+ T cells	0.803813	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.288467	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	0.356775	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.60341	1.23e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	-0.515506	4.55e-38
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD4+ T cells	-0.684498	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Mono/Macro	-0.868755	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.992945	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Mono/Macro	-0.954829	5.07e-08
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-1.29123	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-1.11272	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.671858	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	NK cells	-1.06982	2.26e-10
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.607865	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	0.931626	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	0.567874	5.49e-28
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	1.04106	3.28e-17
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	0.331271	6.04e-03
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	0.692857	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.522039	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.334374	7.14e-14
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-1.42102	0.00e+00

Top

Expression of RPS4Y1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to RPS4Y1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating RPS4Y1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Top

Motifs and transcription factors (TFs) regulating RPS4Y1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
RPS4Y1	hdpi__ZNF695	ZNF695 (directAnnotation).
RPS4Y1	transfac_pro__M02269	FEV (directAnnotation).
RPS4Y1	transfac_pro__M05786	ZNF605 (directAnnotation).
RPS4Y1	taipale_tf_pairs__GCM1_MAX_RTGCGGGNNNNNNNCACGTGN_CAP_repr	GCM1; MAX (directAnnotation).
RPS4Y1	kznf__ZNF736_Imbeault2017_OM_RCADE	ZNF736 (directAnnotation).
RPS4Y1	transfac_pro__M06492	ZNF770 (inferredBy_Orthology).
RPS4Y1	metacluster_181.2	GLIS1; GLIS3 (directAnnotation).
RPS4Y1	swissregulon__mm__Pbx1	PBX1 (inferredBy_Orthology).
RPS4Y1	transfac_pro__M06344	ZNF530 (directAnnotation).
RPS4Y1	transfac_pro__M05853	ZNF548 (directAnnotation).
RPS4Y1	transfac_pro__M06409	ZNF329 (directAnnotation).
RPS4Y1	kznf__GTF3A_Schmitges2016_RCADE	GTF3A (directAnnotation).
RPS4Y1	kznf__ZNF10_Imbeault2017_RP_RCADE	ZNF10 (directAnnotation).
RPS4Y1	taipale_tf_pairs__FLI1_DLX2_RSCGGAARYAATTA_CAP	DLX2; FLI1 (directAnnotation).
RPS4Y1	transfac_pro__M04810	USF2 (directAnnotation).
RPS4Y1	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
RPS4Y1	taipale_tf_pairs__ETV2_SOX15_RSCGGAANNNNNNNYWTTGT_CAP_repr	ETV2; SOX15 (directAnnotation).
RPS4Y1	dbtfbs__ZKSCAN8_representative_N1	ZKSCAN8 (directAnnotation).
RPS4Y1	metacluster_166.5	ERG; ETV2; FLI1 (directAnnotation).
RPS4Y1	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
RPS4Y1	taipale_cyt_meth__CDX2_NRTCGTAAANNN_eDBD_meth	CDX2 (directAnnotation).
RPS4Y1	metacluster_183.3	EHF; ELF3; FLI1; SPIB (directAnnotation). EHF; EHF; ELF2; ELF3; ELF4; ELF5; ERG; ERG; ETV3; ETV6; FLI1; SPI1; SPI1 (inferredBy_Orthology).
RPS4Y1	metacluster_183.4	ETS1 (inferredBy_Orthology).
RPS4Y1	metacluster_138.2	ELF1; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK3; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ERF; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS2; ETS2; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV5; ETV5; FEV; FLI1; FLI1; GABPA; GABPA; KMT2B; SPDEF; SPDEF; SPDEF; ZBTB11; ZNF518A; ZNF580 (directAnnotation). ELF1; ELF2; ELF4; ELK1; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV1; ETV2; ETV3; ETV4; ETV5; FEV; FLI1; FLI1; GABPA; SPDEF; SPDEF (inferredBy_Orthology).
RPS4Y1	transfac_pro__M04937	TCF12 (directAnnotation).
RPS4Y1	tfdimers__MD00210	CDX2; HMBOX1 (directAnnotation).
RPS4Y1	taipale_tf_pairs__ALX4_TBX21_RGGTGYTAATWR_CAP	ALX4; TBX21 (directAnnotation).
RPS4Y1	transfac_pro__M05402	BCL6B (directAnnotation).
RPS4Y1	taipale_tf_pairs__TEAD4_EOMES_NGYGNNAMATWCYNNTMRCRCN_CAP_repr	EOMES; TEAD4 (directAnnotation).
RPS4Y1	transfac_pro__M04849	RELA (directAnnotation).
RPS4Y1	transfac_pro__M05615	ZFP2 (inferredBy_Orthology).
RPS4Y1	tfdimers__MD00595	SREBF1; SREBF2; TBP (directAnnotation).
RPS4Y1	hdpi__ETS1	ETS1 (directAnnotation).
RPS4Y1	metacluster_177.7	ZBTB18; ZBTB18; ZBTB18; ZBTB42 (directAnnotation).
RPS4Y1	tfdimers__MD00031	MYB; ZEB1 (directAnnotation).
RPS4Y1	metacluster_52.11	ZNF184 (directAnnotation).
RPS4Y1	transfac_pro__M06759	ZNF646 (directAnnotation).
RPS4Y1	transfac_pro__M06566	ZNF845 (directAnnotation).
RPS4Y1	metacluster_64.9	NR1I2 (directAnnotation).
RPS4Y1	metacluster_64.8	NR1I2 (directAnnotation).
RPS4Y1	taipale_tf_pairs__ETV2_SOX15_RSCGGAWNNNNNNNACAATRN_CAP_repr	ETV2; SOX15 (directAnnotation).
RPS4Y1	transfac_pro__M06862	ZNF671 (directAnnotation).
RPS4Y1	transfac_pro__M04868	EP300 (directAnnotation).
RPS4Y1	metacluster_191.5	SPDEF (inferredBy_Orthology).
RPS4Y1	transfac_pro__M06408	ZSCAN30 (directAnnotation).
RPS4Y1	transfac_pro__M01153	NR1I2; RXRA (directAnnotation).
RPS4Y1	taipale_tf_pairs__HOXD12_ELK3_RSCGGAAGTAATAAAN_CAP	ELK3; HOXD12 (directAnnotation).
RPS4Y1	metacluster_156.3	DBP; DBP; DBP; DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; TEF; TEF; TEF; TEF; TEF (directAnnotation). DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFILZ; NFILZ; TEF; TEF; TEF; TEF (inferredBy_Orthology).
RPS4Y1	transfac_pro__M06383	ZNF629 (inferredBy_Orthology).
RPS4Y1	hdpi__RAX	RAX (directAnnotation).

Page: 1 2 3 4 5 6 7 8 9

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."